SCHEMBL2020198

SCHEMBL2020198

Cc1ccccc1-c1nnc(N(C)C(C)c2ccccc2)c2ccccc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.39
CYP1A2 P05177 5/20 0.39
CYP2D6 P10635 5/20 0.39
CLK4 Q9HAZ1 5/20 0.39
CYP2C19 P33261 4/20 0.39
MAPK1 P28482 3/20 0.39
SMO Q99835 1/20 0.39
ADORA2A P29274 1/20 0.38
EGFR P00533 1/20 0.35
CSF1R P07333 1/20 0.35
ALDH1A1 P00352 4/20 0.35
NPC1 O15118 3/20 0.35
RAB9A P51151 3/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
KDM4E B2RXH2 3/20 0.35
MAPT P10636 2/20 0.35
HPGD P15428 2/20 0.35
MEN1 O00255 2/20 0.35
LMNA P02545 2/20 0.35
KMT2A Q03164 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2020919 0.86 EGFR (0.39) TSHRCYP1A2CYP2D6CLK4CYP2C19
SCHEMBL2047017 0.85 GBA1 (0.38) ADORA2AEGFRCSF1RNPC1RAB9A
SCHEMBL2017361 0.85 SMO (0.38) TSHRSMOALDH1A1MAPTMEN1
SCHEMBL2019377 0.85 MAPK11 (0.41) EGFRCSF1RALDH1A1NPC1RAB9A
SCHEMBL2021107 0.85 ESR2 (0.40) EGFRCSF1RALDH1A1MAPTMEN1
SCHEMBL2019914 0.85 ESR2 (0.40) EGFRCSF1RALDH1A1MAPTMEN1
SCHEMBL2020839 0.85 ESR2 (0.40) EGFRCSF1RALDH1A1MAPTMEN1
SCHEMBL2053954 0.82 CYP1A2 (0.43) TSHRCYP1A2CYP2D6CLK4CYP2C19
SCHEMBL2017301 0.82 EGFR (0.38) CYP1A2EGFRCSF1RNUDT1RPS6KB1
SCHEMBL2019395 0.82 EGFR (0.38) CYP1A2EGFRCSF1RNUDT1RPS6KB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338591-B2 3-aryl-5,6-disubstituted pyridazines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-12-25 US claimed
US-8338591-B2 3-aryl-5,6-disubstituted pyridazines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-12-25 US disclosed
US-8338591-B2 3-aryl-5,6-disubstituted pyridazines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-12-25 US disclosed
US-20110160187-A1 3-aryl-5,6-disubstituted pyridazines NEUROGEN CORPORATION (US) 2011-06-30 US disclosed
US-20110160187-A1 3-aryl-5,6-disubstituted pyridazines NEUROGEN CORPORATION (US) 2011-06-30 US disclosed
US-20110160187-A1 3-aryl-5,6-disubstituted pyridazines NEUROGEN CORPORATION (US) 2011-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160187-A1 3-aryl-5,6-disubstituted pyridazines MMP25, MMP9, MMP3 TSHR 3648/4885CYP1A2 157/4885CYP2D6 130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.